Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track for NDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics. The merger unites a strong syndicate of institutional investors who are committed to advancing BRIMOCHOL™ PF through marketing approval to patients worldwide while further advancing Tenpoint’s pipeline into clinical development.
Read the full article: Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines //
Source: https://www.businesswire.com/news/home/20241211171904/en/Tenpoint-Therapeutics-Ltd.-and-Visus-Therapeutics-Inc.-Join-Forces-Building-the-Next-Era-of-Best–and-First-in-Class-Ophthalmic-Medicines